CombiMatrix names Whitman to advisory board

Aug. 22, 2005 — Acacia Research Corp. (Nasdaq: CBMX) (Nasdaq: ACTG) announced that Mark Whitman has joined CombiMatrix’s wholly owned subsidiary, CombiMatrix Molecular Diagnostics, as a member of its scientific advisory board and a consultant in the area of melanoma diagnosis and management.

Whitman is the administrative director of surgical services and the director of the melanoma center at Mountainside Hospital, in Montclair, New Jersey.

Whitman has been involved in clinical and basic science research in melanoma dating to his time at the National Cancer Institute, where he was a senior staff fellow in the early 1990s. Most recently, he has been a principal investigator on multiple clinical research trials presented at the annual meetings of the American Society of Clinical Oncology and the Society of Surgical Oncology.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.